Literature DB >> 28877067

Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma.

Ozgur Mete1,2,3, Hasan Gucer4, Mehmet Kefeli5, Sylvia L Asa1,2,3.   

Abstract

The diagnosis of low-grade adrenal cortical carcinoma (ACC) confined to the adrenal gland can be challenging. Although there are diagnostic and prognostic molecular tests for ACC, they remain largely unutilized. We examined the diagnostic and prognostic value of altered reticulin framework and the immunoprofile of biomarkers including IGF-2, proteins involved in cell proliferation and mitotic spindle regulation (Ki67, p53, BUB1B, HURP, NEK2), DNA damage repair (PBK, γ-H2AX), telomere regulation (DAX, ATRX), wnt-signaling pathway (beta-catenin) and PI3K signaling pathway (PTEN, phospho-mTOR) in a tissue microarray of 50 adenomas and 43 carcinomas that were characterized for angioinvasion as defined by strict criteria, Weiss score, and mitotic rate-based tumor grade. IGF-2 and proteins involved in cell proliferation and mitotic spindle regulation (Ki67, p53, BUB1B, HURP, NEK2), DNA damage proteins (PBK, γ-H2AX), regulators of telomeres (DAXX, ATRX), and beta-catenin revealed characteristic expression profiles enabling the distinction of carcinomas from adenomas. Not all biomarkers were informative in all carcinomas. IGF-2 was the most useful biomarker of malignancy irrespective of tumor grade and cytomorphologic features, as juxtanuclear Golgi-pattern IGF-2 reactivity optimized for high specificity was identified in up to 80% of carcinomas and in no adenomas. Loss rather than qualitative alterations of the reticulin framework yielded statistical difference between carcinoma and adenoma. Angioinvasion defined as tumor cells invading through a vessel wall and intravascular tumor cells admixed with thrombus proved to be the best prognostic parameter, predicting adverse outcome in the entire cohort as well as within low-grade ACCs. Low mitotic tumor grade, Weiss score, global loss of DAXX expression, and high phospho-mTOR expression correlated with disease-free survival, but Weiss score and biomarkers failed to predict adverse outcome in low-grade disease. Our results underscore the importance of careful morphologic assessment coupled with ancillary diagnostic and prognostic biomarkers of ACC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28877067     DOI: 10.1097/PAS.0000000000000943

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

Review 1.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

2.  Genetics of aldosterone-producing adenomas with pathogenic KCNJ5 variants.

Authors:  Antonio M Lerario; Kazutaka Nanba; Amy R Blinder; Sachiko Suematsu; Masao Omura; Tetsuo Nishikawa; Thomas J Giordano; William E Rainey; Tobias Else
Journal:  Endocr Relat Cancer       Date:  2019-02-01       Impact factor: 5.678

Review 3.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

Review 4.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 5.  Advances in adrenal tumors 2018.

Authors:  J Crona; F Beuschlein; K Pacak; B Skogseid
Journal:  Endocr Relat Cancer       Date:  2018-07       Impact factor: 5.678

6.  Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma.

Authors:  Wen-Hao Xu; Junlong Wu; Jun Wang; Fang-Ning Wan; Hong-Kai Wang; Da-Long Cao; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Front Genet       Date:  2019-09-11       Impact factor: 4.599

7.  Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma.

Authors:  Vania Balderrama Brondani; Amanda Meneses Ferreira Lacombe; Beatriz Marinho de Paula Mariani; Luciana Montenegro; Iberê Cauduro Soares; João Evangelista Bezerra-Neto; Fabio Yoshiaki Tanno; Victor Srougi; José Luis Chambo; Berenice Bilharinho Mendonca; Madson Q Almeida; Maria Claudia Nogueira Zerbini; Maria Candida Barisson Villares Fragoso
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

Review 8.  The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.

Authors:  Maja Mizdrak; Tina Tičinović Kurir; Joško Božić
Journal:  Biomedicines       Date:  2021-02-10

9.  Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.

Authors:  Zengyuan Zhou; Yuzheng Li; Haiyue Hao; Yuanyuan Wang; Zihao Zhou; Zhipeng Wang; Xia Chu
Journal:  Cell Transplant       Date:  2019-12-11       Impact factor: 4.064

10.  Targeted RNAseq of Formalin-Fixed Paraffin-Embedded Tissue to Differentiate Among Benign and Malignant Adrenal Cortical Tumors.

Authors:  Samuel W Plaska; Chia-Jen Liu; Jung Soo Lim; Juilee Rege; Nolan R Bick; Antonio M Lerario; Gary D Hammer; Thomas J Giordano; Tobias Else; Scott A Tomlins; William E Rainey; Aaron M Udager
Journal:  Horm Metab Res       Date:  2020-08-13       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.